C4 Therapeutics (CCCC) Consolidated Net Income (2019 - 2026)

C4 Therapeutics has reported Consolidated Net Income for 8 years, with the latest figure at -$25.1 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 4.53% year-over-year to -$25.1 million; the trailing twelve-month figure through Mar 2026 stood at -$103.7 million (changed 0.39% YoY), and the FY2025 full-year result was -$105.0 million, changed 0.31% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$25.1 million, down from -$20.4 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$17.7 million in Q2 2024, with the low at -$37.2 million in Q4 2022.
• Average Consolidated Net Income over 5 years is -$29.1 million, with a median of -$28.4 million recorded in 2024.
• Year-over-year, Consolidated Net Income tumbled 137.48% in 2022 and surged 50.68% in 2024.
• Tracing CCCC's Consolidated Net Income over 5 years: stood at -$37.2 million in 2022, then rose by 6.53% to -$34.8 million in 2023, then rose by 0.53% to -$34.6 million in 2024, then jumped by 41.1% to -$20.4 million in 2025, then dropped by 23.39% to -$25.1 million in 2026.
• The last three Consolidated Net Income figures came in at -$25.1 million (Q1 2026), -$20.4 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.

Peer Comparison